- Omeros ( NASDAQ: OMER ) is up 35% in premarket trading after receiving a $200M milestone payment from Rayner Surgical.
- The payment was due to Omeros' ( OMER ) sale of ophthlamic solution Omidria (phenylephrine and ketorolac) in December 2021.
- Leading to the milestone, Omeros ( OMER ) was eligible for a 50% royalty on Omidria sales. That has now dropped to 30%.
- The company noted that the cash infusion will provide funding for continuing operations through at least 2025.
- BiotechValley Insights just wrote that Omeros ( OMER ) is a buy.
For further details see:
Omeros up 35% in premarket trading following $200M milestone payment